Avoro Capital Advisors Reduces $93M in Oruka Therapeutics, Inc. ($ORKA)

Avoro Capital Advisors has completely exited its position in Oruka Therapeutics, Inc. (NasdaqGM:ORKA). According to a recent 13F filing with the SEC, Avoro sold all 1,333,340 shares of the biopharmaceutical company as of May 15, 2026.

What Changed in Avoro Capital Advisors' Oruka Therapeutics Position

Avoro Capital Advisors decided to cut its entire stake in Oruka Therapeutics by selling 1,333,340 shares, leaving it with no holdings in the company. This move represents a 100% reduction from its previous position.

Other Institutional Activity in Oruka Therapeutics

Other institutional investors have shown varied activity in Oruka Therapeutics. FMR LLC increased its holdings by 170,019 shares, ending with over 7.43 million shares valued at approximately $364.51 million. Venrock Adviser, LLC maintained its position with 4.15 million shares worth about $203.48 million. Fairmount Funds Management LLC also held steady with 3.71 million shares valued at $181.74 million. In contrast, BlackRock, Inc. slightly trimmed its position by 12,328 shares, now holding 3.53 million shares valued at $173 million. Paradigm Biocapital Advisors LP significantly boosted its stake by 610,000 shares, bringing its total to 2.32 million shares worth about $113.81 million.

Oruka Therapeutics Stock Snapshot

Shares of Oruka Therapeutics are currently trading at $69.89. The company has a market capitalization of approximately $4.22 billion and a forward P/E ratio of -28.39, indicating it is not yet profitable. The stock has seen a 52-week low of $10.77 and a high of $91.00. Oruka's 50-day moving average is $63.70, and its 200-day moving average is $37.60. The company maintains a strong liquidity position with a current ratio of 23.76 and a quick ratio of 23.38, alongside a debt-to-equity ratio of 0.37.

Recent Earnings

Oruka Therapeutics recently reported its earnings, with EPS figures showing a loss of $1.93. The company did not report revenue growth, maintaining a net margin of zero. The return on equity stands at -27.31%. The next earnings announcement is scheduled for May 13, 2026.

Insider Buying and Selling at Oruka Therapeutics, Inc.

Several insiders have been active in trading Oruka Therapeutics shares. Carl Dambkowski sold 12,583 shares at an average price of $70.11 on June 12, 2026, as part of a planned transaction. He also sold 22,417 shares at $70.13 on June 11, 2026. On the buying side, Samarth Kulkarni purchased 9,136 shares on June 2, 2026, without a planned transaction.

Analysts Set New Price Targets

Analysts remain optimistic about Oruka Therapeutics. On May 14, 2026, BTIG reiterated its 'buy' rating with a price target of $151. HC Wainwright & Co. and UBS maintained their 'buy' ratings with targets of $120 and $100, respectively. The consensus among analysts is a 'strong buy' with a mean target price of $142.17, based on 12 analyst opinions.

About Oruka Therapeutics

Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Menlo Park, California. The company focuses on developing monoclonal antibody therapies for psoriasis and other inflammatory conditions. Its key products include ORKA-001 and ORKA-002, which target specific subunits of interleukin proteins and are in phase 2 trials. Oruka is led by CEO Dr. Lawrence Otto Klein and employs 68 people.

Bottom Line

Avoro Capital Advisors' decision to sell its entire stake in Oruka Therapeutics reflects a significant portfolio change. Investors often track such moves to gauge fund sentiment, though 13F filings are backward-looking and may not represent current positions. Oruka remains a focus in the biotech sector, with strong analyst support and ongoing clinical developments.